[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11202000143PA - Antiproliferative compounds and methods of use thereof - Google Patents

Antiproliferative compounds and methods of use thereof

Info

Publication number
SG11202000143PA
SG11202000143PA SG11202000143PA SG11202000143PA SG11202000143PA SG 11202000143P A SG11202000143P A SG 11202000143PA SG 11202000143P A SG11202000143P A SG 11202000143PA SG 11202000143P A SG11202000143P A SG 11202000143PA SG 11202000143P A SG11202000143P A SG 11202000143PA
Authority
SG
Singapore
Prior art keywords
san diego
international
road
compound
methods
Prior art date
Application number
SG11202000143PA
Inventor
Matthew Alexander
Gerald Artman
Gordon Bray
James Carmichael
Soraya Carrancio
Brian E Cathers
Matthew Correa
Joshua Hansen
Courtney Havens
Timothy Kercher
Antonia Lopez-Girona
Xiaoling Lu
Hon-Wah Man
Mark Nagy
Rama Narla
Joseph Piccotti
Daniel Pierce
Paula Tavares-Greco
Brandon Whitefield
Lilly Wong
Nanfei Zou
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SG11202000143PA publication Critical patent/SG11202000143PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

INTERNATIONAL APPLICATION (19) World Intellectual Property Organization International Bureau PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) vitivio VIII oviolo ~~~~ I D oimIE (43) International Publication Date 17 January 2019 (17.01.2019) (10) International Publication Number WO 2019/014100 Al WIPO I PCT Cmpd No. Total AUC Compd A 1232 Compd 1 1547.5 Figure 1B MICHAEL, James [GB/GB]; 11 Cherry Tree Lane, Ed- walton, Nottingham NG12 4AL (GB). CARRANCIO, So- raya [ES/US]; 5205 Fiore Terrace, Apt. B419, San Diego, CA 92122 (US). CATHERS, Brian E. [US/US]; 10040 Branford Road, San Diego, CA 92129 (US). CORREA, Matthew, D. [US/US]; 9025 Three Seasons Road, San Diego, CA 92126 (US). HANSEN, Joshua [US/US]; 5633 Bellevue Avenue, La Jolla, CA 92037 (US). HAVENS, Courtney, G. [US/US]; 3504 Felton Street, San Diego, CA 92104 (US). KERCHER, Timothy, S. [US/US]; 11283 Paul Barwick Court, San Diego, CA 92126 (US). LOPEZ- GIRONA, Antonia [US/US]; 8959 January Place, San Diego, CA 92122 (US). LU, Xiaoling [CN/US]; 3 Run- nymede Court, Whippany, NJ 07981 (US). MAN, Hon- Wah [US/US]; 27 Grant Way, Princeton, NJ 08540 (US). NAGY, Mark, A. [US/US]; 345 Willowspring Drive N., Encinitas, CA 92024 (US). NARLA, Rama, K. [US/US]; 5157 Great Meadow Drive, San Diego, CA 92130 (US). PICCOTTI, Joseph, R. [US/US]; 742 Rihely Place, Encinitas, CA 92024 (US). PIERCE, Daniel, W. [US/US]; 3406 Lodge Drive, Belmont, CA 94002 (US). TAVARES- GRECO, Paula, A. [BR/US]; 300 Parsippany Road, Par- sippany, NJ 07054 (US). WHITEFIELD, Brandon, W. [US/US]; 6406 Friars Road, #335, San Diego, CA 92108 (US). WONG, Lilly, L. [US/US]; 871 Viva Court, Solana (51) International Patent Classification: A61K 31/496 (2006.01) A61K 31/573 (2006.01) CO7D 241/02 (2006.01) A61P 35/00 (2006.01) A61K 38/05 (2006.01) (21) International Application Number: PCT/US2018/041230 (22) International Filing Date: 09 July 2018 (09.07.2018) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/530,778 10 July 2017 (10.07.2017) US 62/593,185 30 November 2017 (30.11.2017) US 62/675,581 23 May 2018 (23.05.2018) US (71) Applicant: CELGENE CORPORATION [US/US]; 86 Morris Avenue, Summit, NJ 07901 (US). (72) Inventors; and (71) Applicants: ALEXANDER, Matthew, D. [US/US]; 12488 Carmel Cape, San Diego, CA 92130 (US). ART- MAN, Gerald, D., III [US/US]; 8 Halls Mill Road, As- bury, NJ 08802 (US). BRAY, Gordon, L. [US/US]; 301 Main Street, Unit 8C, San Francisco, CA 94105 (US). CAR- (54) Title: ANTIPROLIFERATWE COMPOUNDS AND METHODS OF USE THEREOF (57) : Provided herein is 4-(4-(44(2-(2,6-dioxopiperidin-3-y1)-1-oxoisoin- -• Compound A dolin-4-yfloxy)methypbenzyppiperazin- 1 -y1)-3-fluorobenzonitrile, or an enantiomer, a 600 mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and —v— Compound 1 methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions. 1 2 log[cpd], nM Figure 1A A - I Compound A Compound 1 W O 20 19/0 14100 Al [Continued on next page] WO 2019/014100 Al MIDEDIMOMOIDEIROMOIONIMMEIEDIONHEMOM1011 Beach, CA 92075 (US). ZOU, Nanfei [US/US]; 66 Wood- land Avenue, Fanwood, New Jersey 07023 (US). (74) Agent: BRUNER, Michael, J. et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
SG11202000143PA 2017-07-10 2018-07-09 Antiproliferative compounds and methods of use thereof SG11202000143PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762530778P 2017-07-10 2017-07-10
US201762593185P 2017-11-30 2017-11-30
US201862675581P 2018-05-23 2018-05-23
PCT/US2018/041230 WO2019014100A1 (en) 2017-07-10 2018-07-09 Antiproliferative compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202000143PA true SG11202000143PA (en) 2020-02-27

Family

ID=63036419

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000143PA SG11202000143PA (en) 2017-07-10 2018-07-09 Antiproliferative compounds and methods of use thereof

Country Status (18)

Country Link
US (5) US10357489B2 (en)
EP (1) EP3651766B1 (en)
JP (1) JP7258009B2 (en)
KR (1) KR102656934B1 (en)
CN (1) CN110869021B (en)
AU (2) AU2018301335B2 (en)
BR (1) BR112020000442A2 (en)
CA (1) CA3069138A1 (en)
CL (1) CL2020000060A1 (en)
CO (1) CO2020000193A2 (en)
EC (1) ECSP20001149A (en)
IL (1) IL271889B2 (en)
MX (1) MX2023000085A (en)
SA (1) SA520411007B1 (en)
SG (1) SG11202000143PA (en)
TW (2) TWI830576B (en)
WO (1) WO2019014100A1 (en)
ZA (1) ZA202000157B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7258009B2 (en) * 2017-07-10 2023-04-14 セルジーン コーポレイション Antiproliferative compounds and methods of use thereof
JP2021519337A (en) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Cereblon binder for the degradation of Ikaras
PT3784663T (en) 2018-04-23 2023-10-10 Celgene Corp Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
WO2019226761A1 (en) * 2018-05-23 2019-11-28 Celgene Corporation Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use
MX2020012548A (en) 2018-05-23 2021-05-13 Celgene Corp Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy )methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile.
CN118324742A (en) 2019-01-09 2024-07-12 细胞基因公司 Solid forms comprising oxoisoindole compounds and salts thereof, compositions comprising them and methods of their use
JP7489989B2 (en) 2019-01-09 2024-05-24 セルジーン コーポレイション Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of use thereof
SG11202107413YA (en) 2019-01-09 2021-08-30 Celgene Corp Antiproliferative compounds and second active agents for use in treating multiple myeloma
AR119715A1 (en) 2019-04-12 2022-01-05 Celgene Corp METHODS TO TREAT NON-HODGKIN'S LYMPHOMA WITH THE USE OF 2-(2,6-DIOXOPIPERIDIN-3-IL)-4-((2-FLUORO-4-((3-MORFOLINOAZETIDIN-1-IL)METHYL)BENZYL)AMINO) ISOINDOLIN-1,3-DIONE
MX2021012524A (en) 2019-04-12 2021-11-12 C4 Therapeutics Inc Tricyclic degraders of ikaros and aiolos.
US20240343706A1 (en) 2019-11-27 2024-10-17 Captor Therapeutics S.A. Piperidine-2,6-dione derivatives which bind to cereblon, and methods of use thereof
EP4065576A1 (en) 2019-11-27 2022-10-05 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
JP7408819B2 (en) 2020-01-20 2024-01-05 カング バイオファーマシューティカルズ リミテッド Isoindoline derivatives and pharmaceutical compositions and uses thereof
JP2023523545A (en) * 2020-04-17 2023-06-06 エサイエント ファーマシューティカルズ，インコーポレイティド Modulators of Mas-related G protein receptor X4, related products and methods of use thereof
BR112022020673A2 (en) * 2020-04-30 2023-01-24 Bristol Myers Squibb Co METHODS OF TREATMENT OF ADVERSE EVENTS RELATED TO CYTOKINE
CA3182867A1 (en) 2020-06-25 2021-12-30 Aarif Ahsan Methods for treating cancer with combination therapies
CN113896711A (en) * 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 Heterocyclic immunomodulators
US20230270742A1 (en) 2020-07-07 2023-08-31 Celgene Corporation Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
US20230257366A1 (en) * 2020-07-20 2023-08-17 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof
MX2023001401A (en) 2020-08-03 2023-05-03 Captor Therapeutics S A Low molecular weight protein degraders and their applications.
WO2022146151A1 (en) 2020-12-30 2022-07-07 Captor Therapeutics S.A. Novel compounds which bind to cereblon, and methods of use thereof
AU2022207648A1 (en) 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
EP4347037A1 (en) 2021-05-27 2024-04-10 Celgene Corporation Methods of treating multiple myeloma using combination therapy
WO2022255890A1 (en) 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
WO2022255889A1 (en) 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
EP4380582A1 (en) 2021-08-06 2024-06-12 Celgene Corporation Compositions and methods for selective degradation of engineered proteins
CN116023319A (en) * 2021-10-25 2023-04-28 英格尔医药科技(上海)有限公司 Method for preparing brivaracetam
WO2023138647A1 (en) 2022-01-19 2023-07-27 江苏恒瑞医药股份有限公司 Crystalline form of sulfur-containing isoindoline derivative
WO2024167423A1 (en) 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EE05627B1 (en) 1998-12-23 2013-02-15 Pfizer Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc Agents that modulate immune cell activation and methods of use thereof
US7521051B2 (en) 2002-12-23 2009-04-21 Medimmune Limited Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20060074103A1 (en) 2004-10-06 2006-04-06 Corte James R Cyclic beta-amino acid derivatives as factor Xa inhibitors
BRPI0610235B8 (en) 2005-05-09 2021-05-25 Squibb & Sons Llc genetically modified monoclonal antibodies different from those found in nature, or antigen-binding portion thereof, therapeutic uses thereof, compositions, immunoconjugate, bispecific molecule comprising them, nucleic acid molecule and expression vector
PT1907424E (en) 2005-07-01 2015-10-09 Squibb & Sons Llc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
GB0514018D0 (en) 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
WO2007093540A1 (en) 2006-02-17 2007-08-23 F. Hoffmann-La Roche Ag Benzoyl-piperidine derivatives as 5ht2/d3 modulators
US8022214B2 (en) 2007-01-24 2011-09-20 Polyera Corporation Organic semiconductor materials and precursors thereof
NZ599199A (en) 2007-03-20 2013-10-25 Celgene Corp 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
WO2010057087A1 (en) 2008-11-17 2010-05-20 Plextronics, Inc. Organic photovoltaic devices comprising substituted endohedral metallofullerenes
KR20170113681A (en) 2008-12-09 2017-10-12 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2381777A4 (en) 2008-12-12 2012-08-08 Ariad Pharma Inc Azaindole derivatives as kinase inhibitors
ES2629337T3 (en) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Antibodies against PD-1 and antibodies against PD-L1 and uses thereof
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
NZ700054A (en) * 2010-02-11 2016-03-31 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012037226A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
JP5728921B2 (en) 2010-12-10 2015-06-03 コニカミノルタ株式会社 Optical film, polarizing plate using the same, and liquid crystal display device
US20140018540A1 (en) 2010-12-14 2014-01-16 Electrophoretics Limited Casein kinase 1delta (ck 1delta) inhibitors
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
TW201408652A (en) 2012-07-11 2014-03-01 Hoffmann La Roche Aryl sultam derivatives as RORc modulators
SG10201701057SA (en) * 2012-08-09 2017-03-30 Celgene Corp Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
CN104755472A (en) 2012-09-04 2015-07-01 细胞基因公司 Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione and methods of preparation thereof
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014308704B2 (en) 2013-08-22 2019-10-10 Vanda Pharmaceuticals Inc. Multiple myeloma treatment
EP3172185B1 (en) 2014-07-25 2020-03-04 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
WO2016019386A1 (en) 2014-08-01 2016-02-04 Green Revolution Cooling, Inc. Controller for oil-cooled rack with multiple modes of operation
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
CN107690431A (en) 2015-07-08 2018-02-13 豪夫迈·罗氏有限公司 Aryl sultam derivative as RORc conditioning agents
PL3429591T3 (en) 2016-03-16 2023-07-17 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
CN109415336B (en) 2016-04-06 2023-08-29 密执安大学评议会 MDM2 protein degradation agent
WO2017184995A1 (en) 2016-04-21 2017-10-26 Bioventures, Llc Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
US20190054097A1 (en) 2016-04-21 2019-02-21 Bioventures, Llc Compositions targeting senescent cells and the uses thereof
WO2018039896A1 (en) 2016-08-30 2018-03-08 Dow Global Technologies Llc Method of attenuating concentration of acrolein
JP2019530707A (en) 2016-10-10 2019-10-24 セレラント セラピューティクス インコーポレイテッド Isoquinolidinobenzodiazepine (IQB) -1 (chloromethyl) -2,3-dihydro-1H-benzo [E] indole (CBI) dimer
WO2018071606A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2018075820A2 (en) 2016-10-20 2018-04-26 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
US11541051B2 (en) 2016-12-08 2023-01-03 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating CDK4/6-mediated cancer
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
JP7258009B2 (en) * 2017-07-10 2023-04-14 セルジーン コーポレイション Antiproliferative compounds and methods of use thereof
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
CN109912655B (en) 2017-12-13 2021-12-10 上海科技大学 ALK protein degradation agent and anti-tumor application thereof
CN108690020A (en) 2018-07-04 2018-10-23 清华大学 It is a kind of targeting degradation BET albumen compound and its application
CN108794453A (en) 2018-07-05 2018-11-13 清华大学 It is a kind of targeting degradation FAK albumen compound and its application

Also Published As

Publication number Publication date
TWI830576B (en) 2024-01-21
TW202319385A (en) 2023-05-16
JP2020526534A (en) 2020-08-31
AU2022287569A1 (en) 2023-02-02
WO2019014100A1 (en) 2019-01-17
AU2018301335B2 (en) 2022-09-15
US20200253964A1 (en) 2020-08-13
TW201907923A (en) 2019-03-01
TWI791552B (en) 2023-02-11
MX2023000085A (en) 2023-02-09
US20190008852A1 (en) 2019-01-10
CL2020000060A1 (en) 2020-07-31
EP3651766A1 (en) 2020-05-20
CO2020000193A2 (en) 2020-04-24
SA520411007B1 (en) 2024-08-18
US12029738B2 (en) 2024-07-09
ZA202000157B (en) 2021-08-25
US20190282567A1 (en) 2019-09-19
IL271889B2 (en) 2023-03-01
US10357489B2 (en) 2019-07-23
JP7258009B2 (en) 2023-04-14
US20220280505A1 (en) 2022-09-08
US11185543B2 (en) 2021-11-30
KR102656934B1 (en) 2024-04-16
EP3651766B1 (en) 2024-09-11
CN110869021B (en) 2023-06-30
CN110869021A (en) 2020-03-06
US20240207255A1 (en) 2024-06-27
CA3069138A1 (en) 2019-01-17
AU2018301335A1 (en) 2020-01-30
KR20200026980A (en) 2020-03-11
US10675281B2 (en) 2020-06-09
BR112020000442A2 (en) 2020-07-21
IL271889A (en) 2020-02-27
IL271889B (en) 2022-11-01
ECSP20001149A (en) 2020-02-28

Similar Documents

Publication Publication Date Title
SG11202000143PA (en) Antiproliferative compounds and methods of use thereof
SG11201809714TA (en) Piperidines as menin inhibitors
SG11201807021UA (en) Heteroaryl inhibitors of pad4
SG11201806307YA (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201900596XA (en) Cannabis composition
SG11201901747VA (en) Inhibitors of cellular metabolic processes
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
CA3015496A1 (en) Voice control of a media playback system
SG11201908604YA (en) Fused imidazo-piperidine jak inhibitor compound
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201900665VA (en) Cannabis composition
SG11201907435PA (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201907948TA (en) Formulations comprising pd-1 binding proteins and methods of making thereof
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808337TA (en) Deactivation wipe kit and method of forming and using the same
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201906164RA (en) Bicyclic inhibitors of histone deacetylase
SG11201906222WA (en) Jak1 selective inhibitors